Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17624771 | 0.89 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL17607014 | 0.82 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6791247 | 0.73 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL7111388 | 0.73 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6120490 | 0.73 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL27496485 | 0.73 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL7111393 | 0.73 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL3407785 | 0.73 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL17606882 | 0.71 | MEN1 (0.52) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13752871 | 0.70 | MEN1 (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-16 | — | — | US | disclosed |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| WO-2016042084-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BUB1, BUB1B, BUB3 | MEN1 933/4885KMT2A 2316/4885KDM4C 2553/4885 |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BUB1, BUB1B, BUB3 | MEN1 933/4885KMT2A 2316/4885KDM4C 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.